366 related articles for article (PubMed ID: 2862087)
1. U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.
Diabetes; 1985 Aug; 34(8):793-8. PubMed ID: 2862087
[TBL] [Abstract][Full Text] [Related]
2. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
3. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
4. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
[TBL] [Abstract][Full Text] [Related]
5. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
[TBL] [Abstract][Full Text] [Related]
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
7. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
9. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
Turner R; Cull C; Holman R
Ann Intern Med; 1996 Jan; 124(1 Pt 2):136-45. PubMed ID: 8554206
[TBL] [Abstract][Full Text] [Related]
10. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises.
Umpierrez GE; Clark WS; Steen MT
Diabetes Care; 1997 Apr; 20(4):479-83. PubMed ID: 9096964
[TBL] [Abstract][Full Text] [Related]
11. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
Holman RR; Steemson J; Turner RC
Diabet Med; 1987; 4(5):457-62. PubMed ID: 2959438
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
DeFronzo RA; Goodman AM
N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
[TBL] [Abstract][Full Text] [Related]
13. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
14. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
Wolffenbuttel BH; Weber RF; Weeks L; van Koetsveld PM; Verschoor L
Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
16. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
Matthews DR; Cull CA; Stratton IM; Holman RR; Turner RC
Diabet Med; 1998 Apr; 15(4):297-303. PubMed ID: 9585394
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
[TBL] [Abstract][Full Text] [Related]
18. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
Diabetes; 1995 Nov; 44(11):1249-58. PubMed ID: 7589820
[TBL] [Abstract][Full Text] [Related]
19. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
Roach P; Malone JK
Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
[TBL] [Abstract][Full Text] [Related]
20. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE
Diabetes Care; 2000 Sep; 23(9):1236-41. PubMed ID: 10977012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
